Vincerx Pharma (NASDAQ:VINC – Get Free Report) is anticipated to issue its resultson Friday, March 27th. Analysts expect the company to announce earnings of ($2.20) per share for the quarter.
Vincerx Pharma Stock Performance
Shares of VINC opened at $0.01 on Thursday. The company’s fifty day moving average is $0.01 and its 200 day moving average is $0.02. Vincerx Pharma has a fifty-two week low of $0.00 and a fifty-two week high of $0.69. The stock has a market capitalization of $66,471.80, a PE ratio of 0.00 and a beta of 1.56.
About Vincerx Pharma
Vincerx Pharma, Inc, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for patients with hematologic malignancies and other oncology indications. The company’s research platform centers on selective kinase inhibition and biomarker-driven approaches, with the goal of addressing high unmet medical needs in blood cancers that have limited treatment options.
Vincerx’s lead product candidate, pacritinib—an oral JAK2/IRAK1 inhibitor—was in-licensed from CTI BioPharma Corp.
Recommended Stories
Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
